Siga Technologies (SIGA) Net Income towards Common Stockholders (2010 - 2025)
Siga Technologies (SIGA) posted Net Income towards Common Stockholders of -$6.4 million for Q3 2025, down 117.94% on a QoQ basis from $35.5 million in Q2 2025, and down 573.67% year-over-year from $1.3 million in Q3 2024.
Siga Technologies (SIGA) Net Income towards Common Stockholders (2010 - 2025) Analysis & Trends
Siga Technologies' Net Income towards Common Stockholders history runs 16 years deep, the most recent figure standing at -$6.4 million for Q3 2025.
- Quarterly Net Income towards Common Stockholders fell 573.67% year-over-year to -$6.4 million in Q3 2025, while the trailing twelve-month figure through Dec 2025 was $28.7 million (down 51.65% YoY) and the FY2024 annual result came in at $59.2 million, down 13.01% from the prior year.
- Net Income towards Common Stockholders was -$6.4 million for Q3 2025 at Siga Technologies, down from $35.5 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $73.4 million in Q4 2021 and bottomed at -$6.4 million in Q3 2025.
- A 5-year average of $13.6 million and a median of -$258928.0 in 2021 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders surged 9000.73% — and 2025, when it plunged 573.67%.
- Siga Technologies' Net Income towards Common Stockholders stood at $73.4 million in 2021, then sank by 101.11% to -$811794.0 in 2022, then jumped by 9000.73% to $72.3 million in 2023, then tumbled by 36.45% to $45.9 million in 2024, then plunged by 113.86% to -$6.4 million in 2025.
- Business Quant data shows SIGA's Net Income towards Common Stockholders at -$6.4 million in Q3 2025, $35.5 million in Q2 2025, and -$408223.0 in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -2.35 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Siga Technologies | 223.05 Mn | 68.08 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -6.37 Mn |
| Jun 30, 2025 | 35.48 Mn |
| Mar 31, 2025 | -408,223.00 |
| Dec 31, 2024 | 45.92 Mn |
| Sep 30, 2024 | 1.34 Mn |
| Jun 30, 2024 | 1.80 Mn |
| Mar 31, 2024 | 10.32 Mn |
| Dec 31, 2023 | 72.26 Mn |
| Sep 30, 2023 | -393,066.00 |
| Jun 30, 2023 | -2.88 Mn |
| Mar 31, 2023 | -917,677.00 |
| Dec 31, 2022 | -811,794.00 |
| Sep 30, 2022 | 33.04 Mn |
| Jun 30, 2022 | 1.99 Mn |
| Mar 31, 2022 | -364,455.00 |
| Dec 31, 2021 | 73.38 Mn |
| Sep 30, 2021 | -3.11 Mn |
| Jun 30, 2021 | -258,928.00 |
| Mar 31, 2021 | -1.73 Mn |
| Dec 31, 2020 | 20.16 Mn |